Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Iris Isufi"'
Autor:
Harry Cheung, Sarah Perreault, Geliang Gan, Thomas Holowka, Marwan M. Azar, Maricar Malinis, Yanhong Deng, Iris Isufi
Publikováno v:
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 27(12)
Background Ibrutinib is a small molecule tyrosine kinase inhibitor that blocks the activity of B cells and other immune effectors and is used in a variety of hematologic malignancies. There have been numerous reports of increased frequency of serious
Publikováno v:
Open Forum Infectious Diseases
Background Ibrutinib is a tyrosine kinase inhibitor used to treat hematologic malignancies that may increase the risk of serious infection including invasive fungal infections (IFI). In a study of 378 patients with hematologic malignancy on ibrutinib
Autor:
Francine M. Foss, Stuart Seropian, Sarah Perreault, Jennifer Zhao, Lohith Gowda, Jeffrey E Topal, Dayna McManus, Molly Schiffer, Iris Isufi
Publikováno v:
Open Forum Infectious Diseases
Background Treatment of GvHD with steroids increases the risk of infection in HSCT patients due to additive immunosuppression and may delay the diagnosis of infection due to lack of symptoms. Outpatient surveillance blood cultures in HSCT with GvHD b
Publikováno v:
Open Forum Infectious Diseases
Background Ibrutinib, a tyrosine kinase inhibitor used for treatment of hematologic malignancies, is associated with an increased risk of infection including invasive fungal infections (IFI). However, the risk of infection may vary across different t
Autor:
Maricar Malinis, Francine M. Foss, Stuart Seropian, Iris Isufi, Dayna McManus, Sarah Perreault, Lohith Gowda, Jeffrey E Topal, Noffar Bar
Publikováno v:
Transplant infectious disease : an official journal of the Transplantation Society. 21(2)
BACKGROUND Current guidelines recommend adding vancomycin to empiric treatment of FN in patients who meet specific criteria. After 48 hours, the guidelines recommend discontinuing vancomycin if resistant Gram-positive organisms are not identified. Ba
Autor:
Sarah Perreault, Lohith Gowda, Francine M. Foss, Molly Schiffer, Iris Isufi, Stuart Seropian, Dayna McManus, Jeffrey E Topal
Publikováno v:
Open Forum Infectious Diseases
Background Fever is a common component of cytokine release syndrome (CRS) occurring in 90% of patients undergoing haploidentical hematopoietic stem cell transplantation (Haplo-HSCT). Fevers typically occur between the stem cell infusion (Day 0) and i
Autor:
Noffar Bar, Stuart Seropian, Rebecca Pulk, Jeffrey E Topal, Francine M. Foss, Sarah Perreault, Dayna McManus, Iris Isufi
Publikováno v:
Open Forum Infectious Diseases
Background HSCT patients are at an increased risk of developing PJP after transplant due to treatment induced immunosuppression. Given the risk of cytopenias with co-trimoxazole, AP is utilized as an alternative for PJP prophylaxis. A prior study rev
Autor:
Francine M. Foss, Jeffrey E Topal, Stuart Seropian, Iris Isufi, Sarah Perreault, Dayna McManus, Hiba Ahmad
Publikováno v:
Open Forum Infectious Diseases
Background HSCT patients are at an increased risk of developing infections after transplant due to the loss of immunogenicity from prior vaccinations. Current national and international guidelines recommend routine revaccinations at a fixed dosing sc